Clinical trials: NASH
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of itraconazole or rifampin on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03213145
- Testing
- intraconazole, Rifampin, EDP 305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
NASH
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy human…
- Trial name
- NCT03187496
- Testing
- Midazolam, Caffeine, Rosuvastatin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Liver Fibrosis/NASH
A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body
The purpose of this study is to assess safety, to measure blood levels of drug, and to find out what the drug does to the body.
- Trial name
- NCT02538874
- Testing
- BMS-986171
- Where
- 2 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Non-Alcoholic Steatohepatitis (NASH)
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
The primary objective of this study is to characterize the safety, tolerability and dose-limiting toxicities (DLTs) for GR-MD-02 when administered intravenously to subjects with biopsy-proven NASH with advanced liver fibrosis.
- Trial name
- NCT01899859
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Galectin Therapeutics Inc.
Non-Alcoholic Steatohepatitis(NASH)
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity.
- Trial name
- NCT00706537
- Testing
- Active treatment
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer